Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Morgonrapport
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
    • Insider Transactions
    • Transkriptioner
    • AGM Invitations
  • InderesTV
  • Portfölj
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • Om oss
    • Bolag under bevakning
    • Teamet
Regulatoriskt pressmeddelande

Change in Elekta’s Nomination Committee for the Annual General Meeting 2026

Elekta
Ladda ner börsmeddelandet

STOCKHOLM – Elekta (EKTA-B.ST) announces a change to the company’s Nomination Committee for the Annual General Meeting 2026 to be held on September 3, 2026.

Anna Magnusson has replaced Thomas Wuolikainen as the Fourth Swedish National Pension Fund’s appointed representative on the Nomination Committee.

Following this change, Elekta’s Nomination Committee comprises:

  • Laurent Leksell (Chair of the Nomination Committee), in his capacity as Chair of the Board of Elekta and representing his own and related parties’ holdings
  • Anna Magnusson, appointed by the Fourth Swedish National Pension Fund
  • Katarina Hammar, appointed by Nordea Funds
  • Elisabet Jamal Bergström, appointed by SEB Funds
  • Robin Nestor, appointed by Lannebo Kapitalförvaltning

Shareholders wishing to submit proposals to Elekta’s Nomination Committee can do so by e-mail to Peter.Nyquist@elekta.com or by letter to:

Elekta AB (publ)
Att: Nomination Committee
P.O. Box 7593
SE-103 93 Stockholm
Sweden

In order for the Nomination Committee to be able to process any proposals constructively, these should be received by the Nomination Committee no later than June 5, 2026.

# # #

For further information, please contact:
Peter Nyquist, Head of Investor Relations
Tel: +46 70 575 2906, e-mail: Peter.Nyquist@elekta.com
Time zone: CET (Central European Time)

About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com.

Attachments


Change in Elekta’s Nomination Committee for the Annual General Meeting 2026

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Ta kontakt
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.